Cutaneous Manifestations of HIV and Human T-Lymphotropic Virus
The epidermis and dermis are among the first immune-responsive tissues to reveal how far CD4+ T-cell immunity has fallen in people infected with human immunodeficiency virus (HIV) or human T-lymphotropic virus (HTLV-1/2). These two retroviruses affect the skin in more ways than opportunistic infections alone: they can dramatically alter chronic inflammatory skin diseases, trigger malignant tumors, and provoke immune reconstitution inflammatory syndrome (IRIS).
The two viruses behave very differently. HIV destroys CD4+ T cells directly, leading to acquired immunodeficiency syndrome, whereas HTLV-1 drives malignant transformation of CD4+ T cells, causing adult T-cell leukemia/lymphoma (ATL) as well as severe, long-lasting inflammatory skin disease. Recognizing the characteristic skin lesions accurately is a key clinical clue: it supports early diagnosis of the infection, helps gauge the degree of CD4+ depletion, and guides the best choice of treatment.
At Haute-Derma, we manage skin disease in patients with HIV/HTLV through a standardized, confidential specialist pathway: dermoscopy, skin biopsy with histopathology and immunohistochemistry, viral load testing (HIV RNA and HTLV-1 proviral load), and phototherapy or laser treatments to control symptoms.
Immunopathogenesis and How the Skin Is Affected
HIV and CD4+ T-Cell Depletion
- HIV binds to the CD4 receptor and a co-receptor (CCR5/CXCR4), then enters and kills CD4+ T cells. As CD4+ counts fall, the immune surveillance carried out by Langerhans cells in the epidermis weakens.
- An imbalance between Th1 and Th2 responses promotes hypersensitivity-type skin inflammation and increased IgE production, causing marked flares of psoriasis, seborrheic dermatitis and pruritic papular eruption (PPE).
HTLV-1 and Malignant T-Cell Proliferation
- HTLV-1 encodes the oncoproteins Tax and HBZ, which activate the NF-κB pathway and inactivate p53, driving proliferation of abnormal CD4+ T cells (flower cells).
- The transformed T cells infiltrate the epidermis extensively (epidermotropism) and form Pautrier microabscesses, a hallmark of skin involvement in ATL.
Characteristic Skin Manifestations
Opportunistic Infections:
- Oral hairy leukoplakia (OHL): caused by EBV reactivation in people with HIV (CD4+ < 200 cells/µL). It appears as white, corrugated, wavy plaques along both sides of the tongue that cannot be scraped off.
- Cutaneous Cryptococcosis and Penicilliosis (Talaromycosis): dome-shaped papules with a central depression on the face, easily mistaken for molluscum contagiosum.
- Disseminated or Necrotic Herpes Zoster (Shingles): blisters spanning several dermatomes (multidermatomal), deep necrosis and severe postherpetic pain.
Noninfectious Inflammatory Conditions:
- Severe, Treatment-Resistant Seborrheic Dermatitis: seen in more than 80% of people with HIV. Widespread red plaques with thick, greasy scale cover the face, chest and scalp, and their severity mirrors the degree of CD4+ depletion.
- Pruritic Papular Eruption (PPE): crops of itchy red papules scattered over the arms and legs; in endemic regions this is a clinical sign that should prompt HIV testing.
Neoplastic Manifestations:
- Kaposi Sarcoma (KS, caused by HHV-8): fast-growing deep purple or wine-red patches and nodules on the skin and the mucosa of the palate.
- Adult T-Cell Leukemia/Lymphoma (ATL, caused by HTLV-1): papules, infiltrated red-brown plaques or widespread necrotic tumors, together with enlarged lymph nodes in the neck or groin.
Our Diagnostic Approach at Haute-Derma
Dermoscopy and Mucosal Examination: Rapidly identifies the rainbow pattern typical of Kaposi sarcoma, or abnormal vascular features in HTLV-1-related skin lesions.
Histopathology and Immunohistochemistry (IHC):
- A punch biopsy is sent for specialist dermatopathology review:
- LANA-1 (HHV-8) staining to diagnose Kaposi sarcoma.
- CD3, CD4, CD25 and CCR4 staining to identify the abnormal T-cell clone in HTLV-1-associated ATL.
- PAS/GMS staining to detect deep fungal organisms (Talaromyces marneffei, Cryptococcus).
Immune Status and Viral Load Testing:
- CD4+/CD8+ T-cell counts by flow cytometry.
- Quantitative HIV RNA PCR and HTLV-1 proviral load.
Specialist Management and Treatment at Haute-Derma
Systemic Treatment and Immune Recovery
- Prompt Antiretroviral Therapy (ART): ART (2 NRTIs + 1 INSTI) is started without delay in patients with HIV. Restoring the CD4+ count is the key step, leading to improvement in 70–80% of skin conditions such as seborrheic dermatitis, PPE and early Kaposi sarcoma.
- Monitoring for Immune Reconstitution Inflammatory Syndrome (IRIS): severe inflammatory skin flares in the first 2–12 weeks after starting ART are treated promptly with a short course of systemic corticosteroids.
Device-Based Treatments at Haute-Derma
- Long-Pulsed 1064 nm Nd:YAG Laser / PDL: selectively coagulates the vascular tissue of superficial Kaposi sarcoma, flattening lesions and reducing their purple discoloration.
- Precision Superpulsed CO2 Laser: removes molluscum contagiosum papules, warts and extensive Bowen disease in immunocompromised patients with minimal bleeding.
- Narrowband UVB Phototherapy: used for pruritic papular eruption (PPE) and for treatment-resistant atopic dermatitis or psoriasis in HIV patients whose viral load is under control.
